Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Scientific Research Services
![Ozempic Settles the Obesity Debate: It's Biology Over Willpower](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Ozempic-Settles-the-Obesity-Debate-It039s-Biology-Over-Willpower-400x400.jpeg)
Ozempic Settles the Obesity Debate: It's Biology Over Willpower
- By nasdaqpicks.com
- . 14 August 2023
Weight-loss drugs affect the brain in ways that help researchers understand how the body regulates weight. Source link
![Pfizer’s Covid Boost Crashes to Earth](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Pfizers-Covid-Boost-Crashes-to-Earth-400x400.jpeg)
Pfizer’s Covid Boost Crashes to Earth
- By nasdaqpicks.com
- . 6 August 2023
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.
![Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Venture-Capitalist-Seeks-to-Spur-Drug-Development-for-Rare-Autoimmune-400x400.jpeg)
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
- By nasdaqpicks.com
- . 1 August 2023
Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that
![Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall](http://www.nasdaqpicks.com/wp-content/uploads/2023/08/Pfizer-Misses-Revenue-Expectations-Bets-on-Drug-Launches-to-Ease-400x400.jpeg)
Pfizer Misses Revenue Expectations, Bets on Drug Launches to Ease Shortfall
- By nasdaqpicks.com
- . 1 August 2023
The company is rolling out 19 products or new uses within 18 months, CEO Albert Bourla said. Source link
![Obesity Drugs Won't Starve These Other Potential Blockbusters](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/Obesity-Drugs-Won039t-Starve-These-Other-Potential-Blockbusters-400x400.jpeg)
Obesity Drugs Won't Starve These Other Potential Blockbusters
- By nasdaqpicks.com
- . 7 July 2023
Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly’s medication were published last week. Source link
![OceanGate Suspends Operations After Titan Submersible Implosion That Killed 5](http://www.nasdaqpicks.com/wp-content/uploads/2023/07/OceanGate-Suspends-Operations-After-Titan-Submersible-Implosion-That-Killed-5-400x400.jpeg)
OceanGate Suspends Operations After Titan Submersible Implosion That Killed 5
- By nasdaqpicks.com
- . 7 July 2023
What to Read Next Source link
![Moderna, Merck Show Progress Toward Cancer Vaccines](http://www.nasdaqpicks.com/wp-content/uploads/2023/04/Moderna-Merck-Show-Progress-Toward-Cancer-Vaccines-400x400.jpeg)
Moderna, Merck Show Progress Toward Cancer Vaccines
- By nasdaqpicks.com
- . 17 April 2023
An mRNA shot helped prevent relapse in high-risk melanoma patients. Source link
![Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis](http://www.nasdaqpicks.com/wp-content/uploads/2023/04/Ozempic-Wegovy-and-Mounjaro-Spark-a-Weight-Loss-and-Diet-Industry-400x400.jpeg)
Ozempic, Wegovy and Mounjaro Spark a Weight-Loss and Diet Industry Identity Crisis
- By nasdaqpicks.com
- . 10 April 2023
Weight-loss businesses, which long pushed calorie-counting and willpower, are grappling with the surging popularity of new drugs. Source link
![FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail](http://www.nasdaqpicks.com/wp-content/uploads/2023/04/FTC-Rejects-Illumina039s-7-Billion-Deal-for-Cancer-Test-Developer-Grail-400x400.jpeg)
FTC Rejects Illumina's $7 Billion Deal for Cancer-Test Developer Grail
- By nasdaqpicks.com
- . 3 April 2023
The agency said the combination would hurt competition for cancer-detection tests while raising prices. Source link